An Overview of Gene Therapy in Cardiomyopathies
Scholarly Review Journal · 30.06.2026 · Scholarly Debut (Summer 2026)
DOI: 10.70121/001c.163674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scholarly Review Journal, online erschienen am 30.06.2026. Verfasst von Krisha Patel. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiomyopathies can be treated with gene therapy by correcting disease-causing mutations or reducing harmful gene products. To evaluate therapeutic progress and feasibility, this study compares current evidence between hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and transthyretin amyloid cardiomyopathy (ATTR-CM). In my hypothesis, gene-editing platforms such as CRISPR, base editing, prime editing, RNA interference, gene replacement therapy, and epigenome editing can provide mutation-specific benefits that improve cardiac function regardless of the subtype of cardiomyopathy. Most cases of HCM are caused by mutations in sarcomeres, including MYH7 and MYBPC3. Recent base editing studies have demonstrated successful correction of MYH7 mutations in human cardiomyocytes and humanized mice, restoring structural and functional parameters. A further demonstration of the accuracy and feasibility of targeted correction is provided by the use of CRISPR/Cas9 editing of MYBPC3 (R820W) in feline induced pluripotent stem cells. Prime editing has demonstrated strong potential for treating RBM20-related DCM. Researchers used a single pegRNA to repair multiple RBM20 variants in two cell-based studies, suggesting a versatile therapeutic approach to correct the P633L mutation of RBM20. ATTR-CM is the most advanced clinical trial. Approximately 90% of pathogenic proteins were reduced in a Phase 1 trial based on CRISPR-based TTR editing, with favorable early safety results. RNA-silencing therapy (vutrisiran) similarly stabilized cardiac biomarkers in ongoing clinical analyses.
Zitieren
APA
Patel, K. (2026). An Overview of Gene Therapy in Cardiomyopathies. Scholarly Review Journal, Scholarly Debut(Summer 2026). https://doi.org/10.70121/001c.163674
Vancouver
Patel K. An Overview of Gene Therapy in Cardiomyopathies. Scholarly Review Journal. 2026;Scholarly Debut(Summer 2026). doi:10.70121/001c.163674
BibTeX
@article{Patel2026,
author = {Patel, Krisha},
title = {An Overview of Gene Therapy in Cardiomyopathies},
journal = {Scholarly Review Journal},
year = {2026},
volume = {Scholarly Debut},
number = {Summer 2026},
doi = {10.70121/001c.163674}
}
EUVIMED